LI
Lincoln Pharmaceuticals Ltd (LINCOLN)
₹511.90
Mkt cap
₹1,046 Cr
P/E ratio
10.80
P/B
1.26
Div yield
0.34%
ROE
12.00%
ROCE
16.00%
EPS (TTM)
₹47.40
Book value
₹405
52W range
440–770
Sector
Healthcare
Price history
Previous close
Incorporated in 1979, Lincoln Pharmaceuticals Ltd is in the business of manufacturing and trading of pharmaceutical products [1]
NSE LINCOLNBSE 531633
Health check
Mixed
ValuationCheap
ProfitabilityAverage
GrowthModerate
TechnicalsBearish
52-week range
−33.52% from high₹512
₹440+16.34% from low₹770
Current
₹511.90
Prev close
₹512.05
Day
−0.03%
Price performance
1D
−0.21%
1W
−2.12%
1M
+0.03%
3M
−17.92%
6M
−30.21%
1Y
−2.80%
YTD
+2.97%
Financials
Revenue, profit & margin
P/E ratio
10.8×
LINCOLN is 68% below the sector median of 34.0×
LINCOLN10.8×
Sector median34.0×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 156 | 146 | 142 | 147 | 161 | 147 | 168 | 154 | 163 | 166 | 187 | 177 | 191 | |
| YoY Sales growth | +11% | +9% | +27% | +9% | +3% | +0% | +18% | +5% | +1% | +13% | +11% | +15% | +17% | |
| Expenses | 125 | 117 | 124 | 125 | 133 | 123 | 141 | 130 | 138 | 143 | 162 | 150 | 168 | |
| Operating Profit | 31 | 30 | 18 | 23 | 28 | 24 | 27 | 24 | 25 | 24 | 25 | 27 | 24 | |
| OPM % | 20% | 20% | 13% | 15% | 18% | 16% | 16% | 15% | 16% | 14% | 13% | 15% | 12% | |
| Other Income | 9 | 11 | 7 | 10 | 10 | 9 | -7 | 15 | 7 | 15 | -4 | 24 | 10 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | |
| Profit before tax | 37 | 38 | 22 | 29 | 35 | 29 | 16 | 35 | 29 | 35 | 17 | 48 | 29 | |
| Tax % | 25% | 26% | 16% | 20% | 24% | 28% | 29% | 22% | 31% | 18% | 30% | 24% | 30% | |
| Net Profit | 28 | 28 | 19 | 24 | 26 | 21 | 12 | 28 | 20 | 29 | 12 | 36 | 20 | |
| EPS in Rs | 13.80 | 14.00 | 9.29 | 11.82 | 13.15 | 10.37 | 5.78 | 13.82 | 9.98 | 14.28 | 5.81 | 18.09 | 10.20 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.20% · closed higher next day 22 of last 43
| Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | Q2FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 8 Feb '24 | 16 May '24◦ | 8 Aug '24 | 14 Nov '24 | 13 Feb '25 | 22 May '25◦ | 7 Aug '25 | 13 Nov '25◦ | 12 Feb '26◦ | 28 May '26◦ | 13 Aug '26 | 29 Oct '26 |
| Earnings day | −2.10% | +0.86% | −1.94% | −2.03% | −3.51% | +1.61% | +13.17% | +3.89% | +6.25% | −16.51% | +4.50% | −2.08% |
| +1 day | −1.96% | +0.59% | −0.31% | −2.44% | −15.45% | +1.81% | +5.87% | +5.31% | +1.26% | −20.04% | +3.47% | +0.45% |
| +5 days | −5.19% | −0.94% | −1.15% | −2.22% | −15.08% | −1.41% | +2.17% | +4.57% | +1.10% | −17.49% | +5.02% | −0.46% |
| +15 days | +1.93% | +5.11% | +6.67% | +51.48% | −14.84% | +6.58% | +2.30% | −2.54% | +0.13% | −18.93% | +5.03% | — |
| +30 days | −10.50% | +12.63% | +9.82% | +25.13% | −16.92% | +2.24% | +3.63% | −6.59% | −3.40% | −19.48% | −0.31% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Sep 202649.78%Promoter
Promoters49.78%
FIIs4.55%0.05
DIIs0.02%0.25
Public45.65%0.29
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,880.00 | 36.66 | 4,51,075 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,442.00 | 88.89 | 3,03,749 | 0.26% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,670.00 | 81.82 | 1,77,632 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,424.00 | 97.75 | 1,30,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,189.90 | 26.20 | 1,18,693 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,380.00 | 41.17 | 1,15,267 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,391.80 | 36.21 | 1,12,442 | 0.93% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Lincoln Pharma. | ₹522.05 | 10.79 | 1,046 | 0.34% | 20 | +2.25% | 191 | +17.13% | 16.02% |
| Median: 160 Co. | ₹465.83 | 33.99 | 2,012 | 0.08% | 13 | +33.53% | 179 | +20.92% | 14.94% |
Filings
Annual reports15
Concall transcripts36
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 30 Oct - Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, we enclosed herewith the copies of newspaper intimation with respect to un-audited financial results for the …Un-Audited Financial Results For The Quarter And Half Year Ended On September 30, 2026. 29 OctBoard Meeting Outcome for Board Meeting Outcome For Un-Audited Financial Results For The Quarter And Half Year Ended On September 30, 2026. 29 Oct - Board approved Q2 and H1 FY27 results; consolidated net profit rose 20.52% to Rs.57.50 crore.Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter And Half Year Ended 30.09.2026. 22 Oct - Board meeting on 29 Oct 2026 to approve Q2 and half-year FY2026 results; trading window closed1 Oct.Announcement under Regulation 30 (LODR)-Change in Management 17 Oct - Senior General Manager-Quality Assurance Pradeep Kumar Yadav resigned effective October 17, 2026.






